NRC FORM 591M PART 1 (07-2012)	U.S. NUCLEAR REGULATORY COMMISS			
10 CFR 2.201	SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION			
1. LICENSEE/LOCATION INSPECTED		2. NRC/REGIONAL OFFICE		
Nemours - Alfred I. duPont Hospital for Children 1600 Rockland Road Wilmington, DE		Region 1 2100 Renaissance Blvd Suite 100 King of Prussia, PA 19406-2713		
REPORT NUMBER(s) 20210	01			

5. DATE(S) OF INSPECTION

05/24/2021 - 08/11/2021

4. LICENSE NUMBER(S)

07-16199-02

 10 CFR 35.24(f) requires, in part, that the Radiation Safety Committee (RSC) must include an authorized user of each type of use permitted by the license.

Contrary to the above, from June 5, 2018 to May 24, 2021, Nemours – Alfred I. duPont Hospital for Children's RSC did not include an authorized user of each type of use permitted by the license. Specifically, the RSC did not include an authorized user of Yttrium-90 microspheres permitted by 10 CFR 35.1000.

This is a Severity Level IV violation (Enforcement Policy Section 6.3). Corrective actions included appointing an Yttrium-90 microsphere authorized user to the RSC and inviting them to attend the meetings. In addition, the Radiation Safety Officer (RSO) will now be taking attendance to ensure that all required members are in attendance.

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE	Mark Mumford, Chief Executive of Delaware Valley Operations	Mal Mul	9/9/2021
NRC INSPECTOR	Janice Nguyen		nec by Janice E. Nguyen 09.07 17:14:27 -04'00'
BRANCH CHIEF	Tara Weidner		

3. DOCKET NUMBER(S)

030-19939

NRC FORM 591M PART 1 (07-2012)		U.S. NUCLEAR REGULATORY COMMISSION					
07-2012) 10 CFR 2.201 SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION							
1. LICENSEE/LOCATION INSPECTED		2. NRC/REGIONAL OFFICE					
Nemours - Alfred I. duPont Hospital fo 1600 Rockland Road Wilmington, DE	r Children	Region 1 2100 Renaissance Blvd Suite 100 King of Prussia, PA 19406-2713					
REPORT NUMBER(s) 2021001							
3. DOCKET NUMBER(S)			5. DATE(S) OF INSPECTION				
030-19939	07-16199-02		05/24/2021 - 08/11/2021				
LICENSEE: The Inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The Inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the Inspector. The inspection findings are as follows: 1. Based on the inspection findings, no violations were identified.							
2, Previous violation(s) closed.							
3. The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.							
Non-cited violation(s) were discussed involving the following requirement(s):							
Markey Comments							
4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with the NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11. (Violations and Corrective Actions)							
10 CFR 35.75(a) requires, in part, that a licensee may authorize the release from its control any individual who has been administered to be unsealed byproduct material if the total effective dose equivalent to any other individual from exposure to the released individual is not likely to exceed 5 mSv (0.5 rem).							
Contrary to the above, the licensee released from its control individuals who had been administered unsealed byproduct material without determining the total effective dose equivalent to any other individual from exposure to the released individual. Specifically, on August 22, 2019, November 15, 2019, June 12, 2020, and July 17, 2021, Nemours – Alfred I. duPont Hospital for Children released individuals who were administered more than 33 millicuries of Iodine-131 without performing release calculations to demonstrate that the total effective dose equivalent to any other individual from exposure to the released individuals was not likely to exceed 5 mSv (0.5 rem).							
This is a Severity Level IV violation (Enforcement Policy Section 6.7). Corrective actions included performing the release calculations for the four patients and determining that the total effective dose equivalent to any other individual from exposure to the released individuals did not exceed 0.226 rem. In addition, the licensee developed a spreadsheet to perform future patient release calculations and this page will be included on the last page of the written directive. The staff were provided training on the new process.							
v.							